- Home
- GDO vs GNLX Comparison
GDO vs GNLX Comparison
Compare GDO & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$4.20
Company Overview
Basic Information| Metric | GDO | GNLX |
|---|---|---|
| Founded | 2009 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.6M | 202.4M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | GDO | GNLX |
|---|---|---|
| Price | $11.84 | $4.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.75 |
| AVG Volume (30 Days) | 39.4K | ★ 157.5K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 9.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.21 | $1.99 |
| 52 Week High | $13.04 | $8.54 |
Technical Indicators
Market Signals| Indicator | GDO | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 61.19 | 35.32 |
| Support Level | $11.63 | $4.00 |
| Resistance Level | $11.90 | $4.37 |
| Average True Range (ATR) | 0.12 | 0.32 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 93.10 | 13.94 |
Price Performance
Historical Comparison GDO
GNLX
About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.